Study Report
Reference
| Citation | Ferguson, 2002 PubMed |
| Full Info | Ferguson, J.M., Mendels, J. and Schwart, G.E. (2002) Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression. Int Clin Psychopharmacol, 17, 45-51.
|
Study
| Hypothesis or Background |
Reboxetine is the first selective norepinephrine reuptake inhibitor (NRI) approved for the treatment of major depressive disorder (MDD). Although reboxetine has demonstrated efficacy for the treatment of depression, its effects on specific depressive symptoms have not been reported.
|
| Sample Information | patients with MDD |
|---|
| Method Detail | We evaluated the effects of reboxetine on four Hamilton Depression Rating Scale (HAM-D) factors: psychomotor retardation, anxiety, cognitive disturbance and insomnia. Data were obtained from four short-term (4-8-week), randomized, placebo-controlled trials of reboxetine for the treatment of MDD. For each study, mean changes in HAM-D symptom factor scores from randomization to the study endpoint were compared between reboxetine and placebo. In addition, data from all four studies were pooled to determine the proportions of patients who either improved or worsened with treatment were compared between placebo (n = 353) and reboxetine (n = 350) treatment groups. |
| Method Keywords | psychometric method; dose administration |
| Result | Compared to placebo, reboxetine significantly improved psychomotor retardation in all four trials. Cognitive disturbance and anxiety were improved in three of four trials, and insomnia was improved in one trial with a positive trend in the second trial. |
| Conclusions | Reboxetine, a selective NRI, improves symptoms of psychomotor retardation, anxiety and cognitive disturbance during treatment of MDD. |
Relationships reported by
Ferguson, 2002
| Component A Approved Name (Name in Paper) |
Component A Type |
Component B Approved Name (Name in Paper) |
Component B Type |
Statistical Result |
Relationship Description |
Result Category (Positive/Negative)) |
|
Low energy (psychomotor retardation)
|
symptoms |
Norepinephrine (norepinephrine) |
molecule |
|
Reboxetine, a selective NRI(norepinephrine reuptake inhibitor), improves symptoms of psychomotor retardation, anxiety and cognitive disturbance during treatment of MDD. Compared to placebo, reboxetine significantly improved psychomotor retardation in all four trials. |
Positive
|
|
Increased agitation (anxiety)
|
symptoms |
Norepinephrine (norepinephrine) |
molecule |
|
Reboxetine, a selective NRI(norepinephrine reuptake inhibitor), improves symptoms of psychomotor retardation, anxiety and cognitive disturbance during treatment of MDD. Cognitive disturbance and anxiety were improved in three of four trials. |
Positive
|
|
MDD
|
syndrome |
Norepinephrine (norepinephrine) |
molecule |
|
Reboxetine is the first selective norepinephrine reuptake inhibitor (NRI) approved for the treatment of major depressive disorder (MDD). |
Positive
|
|
Cognitive performance (cognitive disturbance)
|
cognition and behavior |
Norepinephrine (norepinephrine) |
molecule |
|
Reboxetine, a selective NRI(norepinephrine reuptake inhibitor), improves symptoms of psychomotor retardation, anxiety and cognitive disturbance during treatment of MDD. Cognitive disturbance and anxiety were improved in three of four trials. |
Positive
|
